Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DCTPP1 | Q9H773 | 10/20 | 0.38 |
| ▸ | SCD | O00767 | 2/20 | 0.37 |
| ▸ | IDH1 | O75874 | 1/20 | 0.37 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.35 |
| ▸ | MMP1 | P03956 | 1/20 | 0.34 |
| ▸ | MMP2 | P08253 | 1/20 | 0.34 |
| ▸ | MMP9 | P14780 | 1/20 | 0.34 |
| ▸ | MMP13 | P45452 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1812202 | 0.82 | SCD (0.51) | SCD | |
| SCHEMBL1818131 | 0.74 | LMNA (0.36) | CHRNA7 | |
| SCHEMBL5184184 | 0.73 | DPP7 (0.41) | — | |
| SCHEMBL937146 | 0.73 | DRD4 (0.50) | — | |
| SCHEMBL8168773 | 0.70 | FUCA1 (0.50) | — | |
| SCHEMBL27634139 | 0.68 | HTR1A (0.52) | DCTPP1SCD | |
| SCHEMBL936514 | 0.68 | HDAC1 (0.41) | CHRNA7 | |
| SCHEMBL18484463 | 0.68 | KMT2A (0.41) | — | |
| SCHEMBL7867642 | 0.68 | KMT2A (0.41) | — | |
| SCHEMBL14820140 | 0.68 | KMT2A (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1785747-B1 | Ophthalmic contact lens with a coating protecting it against photodegradation and preparation process for such a contact lens | ESSILOR INT (FR) | 2018-02-28 | — | — | EP | disclosed |
| US-20070299081-A1 | Heterocyclic Derivatives and Their Use as Mediators of Stearoyl-Coa Desaturase | XENON PHARMACEUTICALS INC. (CA) | 2007-12-27 | — | — | US | disclosed |
| EP-1799668-A1 | HETEROCYCLIC DERIVATIVES AND THEIR USE AS MEDIATORS OF STEAROYL-COA DESATURASE | XENON PHARMACEUTICALS INC. (CA) | 2007-06-27 | — | — | EP | disclosed |
| EP-1785747-A1 | Ophthalmic contact lens with a coating protecting it against photodegradation and preparation process for such a contact lens | ESSILOR INTERNATIONAL (COMPAGNIE GENERALE D'OPTIQUE) (FR) | 2007-05-16 | — | — | EP | disclosed |
| WO-2006034338-A1 | HETEROCYCLIC DERIVATIVES AND THEIR USE AS MEDIATORS OF STEAROYL-COA DESATURASE | XENON PHARMACEUTICALS INC. (CA) | 2006-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299081-A1 | Heterocyclic Derivatives and Their Use as Mediators of Stearoyl-Coa Desaturase | SCD, SCD5, NR1H2 | DCTPP1 4073/4885SCD 1/4885IDH1 459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.